U.S. Metals and Mining Stock News

NasdaqCM:ENGS
NasdaqCM:ENGSConstruction

Energys Group (ENGS) Slides After Weaker Earnings and Delayed Filing Can Operational Stability Hold?

Energys Group Limited recently reported full-year earnings for the period ending June 30, 2025, revealing sales of £6.89 million and a net loss of £2.08 million, both weaker than the previous year. The announcement also included a delayed SEC filing, which can heighten investor concerns regarding financial transparency and regulatory compliance. We’ll examine how the declining sales and rising losses affect Energys Group’s investment narrative and outlook for operational stability. Find...
NasdaqGS:CLNE
NasdaqGS:CLNEOil and Gas

Clean Energy Fuels (CLNE): Assessing Valuation Following Q3 Beat and Major RNG Expansion Moves

Clean Energy Fuels (CLNE) just posted third-quarter results that surpassed revenue and EBITDA expectations. The company also advanced multiple renewable natural gas projects and signed several new supply agreements. Its efforts in ramping up RNG production and expanding partnerships are catching investors’ eyes. See our latest analysis for Clean Energy Fuels. Despite Clean Energy Fuels’ operational progress and upbeat earnings surprise, the 1-year total shareholder return of -31.3% and a...
NYSE:JELD
NYSE:JELDBuilding

JELD-WEN (JELD) Is Down 41.0% After Job Cuts, Losses, and European Business Review—Has the Bull Case Changed?

JELD-WEN Holding, Inc. recently reported third-quarter 2025 results revealing a drop in sales to US$809.5 million and a net loss of US$367.6 million, alongside plans to cut approximately 850 jobs, goodwill impairment charges of US$196.9 million, and a lowered full-year revenue outlook. The company also announced a review of strategic alternatives for its European business, which accounted for roughly US$1.1 billion in 2024 revenue, highlighting a significant reevaluation of its global...
NYSE:ALB
NYSE:ALBChemicals

Albemarle (ALB): Ongoing Losses Challenge Bullish Turnaround Narratives Despite Strong Profitability Forecasts

Albemarle (ALB) remains unprofitable, with reported losses having increased at an average rate of 22.5% per year across the last five years and no improvement shown in net profit margins in its most recent filing. Despite these challenges, the company’s earnings are forecast to rebound sharply at a predicted 66.75% annual growth rate, with profitability expected within three years. Revenue is projected to climb by 8.5% per year, which is slower than the US market average of 10.4%. See our...
NasdaqGS:ARAY
NasdaqGS:ARAYMedical Equipment

Accuray (ARAY) Losses Increase 28.3% Annually, Challenging Turnaround Narrative Despite Profitability Forecast

Accuray (ARAY) has remained unprofitable, with losses deepening at an annual rate of 28.3% over the past five years. While revenue is projected to grow at 4.4% per year, which is slower than the broader US market’s 10.4% average, earnings are expected to rise sharply at 116.63% per year. This sets the company on course to become profitable within three years. With a Price-To-Sales Ratio of 0.3x and the current share price trading below the estimated fair value of $5.17, investors are keeping...
NasdaqCM:OCGN
NasdaqCM:OCGNBiotechs

Ocugen (OCGN): Valuation Pressures Challenge Bullish Narrative as Profitability Remains Elusive

Ocugen (OCGN) is projected to deliver rapid revenue growth of 75.3% per year, with earnings expected to rise 77.45% annually, both far exceeding the broader US market estimates. The company remains unprofitable, having posted a 3.8% average annual increase in losses over the past five years, and its share price currently trades at $1.38. Investors will weigh these aggressive growth forecasts against Ocugen’s continued net margin struggles and premium valuation, especially given a...